|
Sign In to gain access to subscriptions and/or personal tools.
|
5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy
Gerald M Higa, PharmD
Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA; School of Pharmacy, West Virginia University, Morgantown, WV, USA; Department of Medicine, Section of Hematology-Oncology, West Virginia University, Morgan-town, WV, USA; WVU School of Pharmacy, Robert C. Byrd Health Sciences Center, PO Box 9520, West Virginia University, Morgantown, WV 26506-9520, USA ghiga{at}hsc.wvu.edu
Miklos L Auber, MD
Ramin Altaha, MD
Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA; Department of Medicine, Section of Hematology-Oncology, West Virginia University, Morgan-town, WV, USA
Debbie Piktel, BS
Department of Immunology and Microbiology, West Virginia University, Morgantown, WV, USA
Sohba Kurian, MD
Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA; Department of Medicine, Section of Hematology-Oncology, West Virginia University, Morgantown, WV, USA
Gerry Hobbs, PhD
Department of Community Medicine, West Virginia University, Morgantown, WV, USA
Kenneth Landreth, PhD
Department of Immunology and Microbiology, West Virginia University, Morgantown, WV, USA
Background. Even though direct cause and effect has not been proved, clinical evidence suggests serotonin and substance P (SP) are involved in the emetic response following chemotherapy. Because of several parallels, we hypothesized that SP release, like serotonin, may be propagated by chemotherapy and both substances can be measured in biological fluids, and correlated with a particular phase of emesis.
Methods. Urinary 5-hydroxyindoleacetic acid (5-HIAA) was assessed by HPLC; serum and urine SP were measured by immunoassay. In addition to construction of neurotransmitter profiles, all SP data were grouped according to cisplatin dosages, = or>75 mg/m 2 versus <75 mg/m2, and phase of emesis, acute versus delayed. Analyses of these data were performed by repeated measures analysis of variance.
Results. Samples were collected over a 72-hour period from 26 adult patients who received cisplatin-(n=13) or non-cisplatin-containing (n=13) chemotherapy. Mean baseline 5-HIAA: creatinine ratios were 5.23 and 5.16 in females and males, respectively; mean baseline SP levels were 392 and 181 pg/mL in females and males, respectively. Comparisons between SP data stratified by cisplatin dosage and emetic phase were significantly different, P <0.0001.
Conclusions. Laboratory studies provide additional evidence that serotonin and SP are involved primarily, though not exclusively, in acute and delayed vomiting, respectively.
Key Words: substance P • 5-HIAA • NK1 receptor • 5-HT3 receptor
References
- Borison HL, Wang SC. Physiology and pharmacology of vomiting . Pharmacol Rev 1953; 5: 193 230 .[Medline]
[Order article via Infotrieve]
- Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress . Oncology (Huntingt) 2004; 18: 9-14 .
- Veyrat-Follet C, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy . Drugs 1997; 53: 206-234 .[Medline]
[Order article via Infotrieve]
- Cubeddu LX. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients . Oncology 1996; 53: 18-25 .[Medline]
[Order article via Infotrieve]
- de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists . Br J Cancer 1997; 76: 1055-1061 .[Medline]
[Order article via Infotrieve]
- du Bois A, Vach W, Siebert C et al. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens . Support Care Cancer 1997; 5: 212-218 .[CrossRef][Medline]
[Order article via Infotrieve]
- Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy . Cancer 1993; 72: 2239-2241 .[CrossRef][Medline]
[Order article via Infotrieve]
- Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics . J Clin Pharmacol 1993; 33: 691-697 .[Abstract]
- Latreille J, PaterJ, Johnston D et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy . J Clin Oncol 1998; 16: 1174-1178 .[Abstract]
- Olver I, Paska W, Depierre A et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatininduced delayed emesis . Ann Oncol 1996; 9: 945-952 .
- Gandara DR, Harvey W, Moaghan GG, Perez EA, Hesketh PJ. Delayed emesis following high-dose cisplatin: A double-blind randomized comparative trial of ondansetron (GR38032F) versus placebo . Eur J Cancer 1993; 29A: 35-38 .
- Martin M. The severity and pattern of emesis following different cytotoxic agents . Oncology 1996; 53: 26-31 .[Medline]
[Order article via Infotrieve]
- Cocquyt V, Van Belle S, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis . Eur J Cancer 2001; 37: 835-842 .[CrossRef][Medline]
[Order article via Infotrieve]
- Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics . Drugs 2000; 60: 535-546 .
- Heitz P, Polak JM, Timson DM, Pearse AG. Enterochromaffin cells as the endocrine source of gastrointestinal substance P . Histochemistry 1976; 49: 343-347 .[CrossRef][Medline]
[Order article via Infotrieve]
- Andrews PLR, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret . Neuropharmacology 1993; 32: 799-806 .[CrossRef][Medline]
[Order article via Infotrieve]
- Sasek CA, Wessendorf MW, Helke CJ. Evidence for coexistence of thyrotropin-releasing hormone, substance P and serotonin in ventral medullary neurons that project to the intermediolateral cell column of the rate . Neuroscience 1990; 35: 105-119 .[CrossRef][Medline]
[Order article via Infotrieve]
- Sanger GJ. The involvement of 5-HT3 receptors in visceral function. In Hamon M ed. Central and peripheral 5-HT3 receptors. Academic Press , 1992: 207-255.
- Tattersall FD, Rycroft W, Francis B et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets . Neuropharmacology 1996; 35: 1121-1129 .[CrossRef][Medline]
[Order article via Infotrieve]
- Uemura M, Tsujii T, Kikuchi E et al. Increased plasma levels of substance P and disturbed water excretion in patients with liver cirrhosis . Scand J Gastroenterol 1998; 33: 860-866 .[CrossRef][Medline]
[Order article via Infotrieve]
- Kris MG, Hesketh PJ, Herrstedt J et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy . Support Care Cancer 2005; 13: 85-96 .[CrossRef][Medline]
[Order article via Infotrieve]
- Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology . J Clin Oncol 1999; 17: 2971-2994 .[Free Full Text]
- Hesketh PJ, Van Belle S, Aapro M et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists . Eur J Cancer 2003; 39: 1074-1080 .[CrossRef][Medline]
[Order article via Infotrieve]
- Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin the Aprepitant Protocol 052 Study Group . J Clin Oncol 2003; 21: 4112-4119 .[Abstract/Free Full Text]
- Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting . Cancer 2003; 97: 2290-2300 .[CrossRef][Medline]
[Order article via Infotrieve]
- Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758298 and MK-0869 . Cancer 2002; 94: 3032-3041 .[CrossRef][Medline]
[Order article via Infotrieve]
- Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone . J Clin Oncol 2001; 19: 1759-1767 .[Abstract/Free Full Text]
- Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist . N Engl J Med 1999; 340: 190-195 .[Abstract/Free Full Text]
- Alfieri AB, Cubeddu LX. Treatment with para-chlorophenylalanine antagonizes the emetic response and the serotonin-releasing actions of cisplatin in cancer patients . Br J Cancer 1995; 71: 629-632 .[Medline]
[Order article via Infotrieve]
- Aapro M. Methodological issues in antiemetic studies . Invest New Drugs 1993; 11: 243-253 .[CrossRef][Medline]
[Order article via Infotrieve]
- Janes RJ, Muhonen T, Karjalainen UP, Wiklund T. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple day high-dose chemotherapy . Eur J Cancer 1998; 34: 196-198 .[CrossRef][Medline]
[Order article via Infotrieve]
- Navari RM, Madajewicz S, Anderson N et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind randomized comparative trial of ondansetron versus placebo . J Clin Oncol 1995; 13: 2408-2416 .[Abstract/Free Full Text]
- Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy . J Clin Oncol 1997; 15: 103-109 .[Abstract/Free Full Text]
- Yanaihara C, Sato H, Hirohashi M, Sakagami M, Yamamoto K. Substance P radioimmunoassay using N-a-tyrosyl-sub-stance P and demonstration of the presence of substance P-like immunoreactivity in human blood and porcine tissue extracts . Endocrinol Jpn 1976; 23: 457-463 .[Medline]
[Order article via Infotrieve]
- Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy . J Clin Oncol 1995; 13: 681-687 .[Abstract/Free Full Text]
- Schroder CP, van der Graaf WT, Kema IP, Groenewegen A, Sleijfer DT, de Vries EG. Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron . Cancer Chemother Pharmacol 1995; 36: 477-482 .[Medline]
[Order article via Infotrieve]
Journal of Oncology Pharmacy Practice, Vol. 12, No. 4,
201-209 (2006)
DOI: 10.1177/1078155206072080
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. C. De Jonghe and C. C. Horn
Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus)
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2009;
296(4):
R902 - R911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. De Jonghe and C. C. Horn
Chemotherapy-induced pica and anorexia are reduced by common hepatic branch vagotomy in the rat
Am J Physiol Regulatory Integrative Comp Physiol,
March 1, 2008;
294(3):
R756 - R765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hartvig
Letter to the editor
Journal of Oncology Pharmacy Practice,
March 1, 2007;
13(1):
57 - 58.
[PDF]
|
|
|
|
|
